{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:23:48Z","timestamp":1787657028604,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Michigan Department of Radiology Seed Grant","award":["U090365"],"award-info":[{"award-number":["U090365"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is an aggressive subtype with high chemoresistance and poor survival rates. While mitochondrial dynamics, fission and fusion, are implicated in chemoresistance, their precise roles remain largely unexplored. This study investigates how cytoplasmic phosphatases SHP-1 and SHP-2 regulate chemotherapeutic response in TNBC cells with altered mitochondrial dynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized click beetle green luciferase-expressing SUM149 and SUM159 TNBC cells engineered to stably express mitochondrial dynamics modulators (PISD, Drp1, MFN2). SHP-1\/2 activity was further manipulated using either the inhibitor NSC87877 or stable shRNA knockdown, confirmed by qRT-PCR and Western Blotting. Cell growth and cytotoxicity were evaluated through bioluminescence imaging and drug assays using doxorubicin, paclitaxel, and salinomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We show that SUM149 and SUM159 TNBC cells engineered to exhibit enhanced mitochondrial fission via increased PISD and Drp1 expression are more sensitive to doxorubicin and salinomycin, but not paclitaxel. SHP-1\/2 inhibition attenuated doxorubicin and salinomycin sensitivity specifically in mitochondrial fission-enriched cells, with minimal effects in fusion-enriched cells and no effect on paclitaxel response. Notably, only SHP-1 knockdown reduced drug sensitivity in cells with enhanced mitochondrial fission, highlighting SHP-1 as a key regulator of chemoresistance. Conversely, enhanced mitochondrial fusion conferred resistance to cytotoxic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our\n                      <jats:italic>in vitro<\/jats:italic>\n                      findings demonstrate that mitochondrial fission sensitizes TNBC cells to certain chemotherapeutics, and that SHP-1 critically regulates this response. This newly identified mechanism links mitochondrial dynamics to chemotherapeutic sensitivity, offering a potential pathway to overcome TNBC chemoresistance through targeted therapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-026-12615-y","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:08:09Z","timestamp":1787656089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced mitochondrial fission promotes chemosensitivity via SHP-1 activity in triple-negative breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Elizabeth K.","family":"Croom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian E.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro J.","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock A.","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"22","key":"12615_CR1","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463\u20135472","journal-title":"Cancer"},{"issue":"4","key":"12615_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE (2018) Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173(4):879-893 e813","journal-title":"Cell"},{"issue":"4","key":"12615_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown KK, Spinelli JB, Asara JM, Toker A (2017) Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov 7(4):391\u2013399","journal-title":"Cancer Discov"},{"issue":"5","key":"12615_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.cmet.2017.09.006","volume":"26","author":"S Andrzejewski","year":"2017","unstructured":"Andrzejewski S, Klimcakova E, Johnson RM, Tabaries S, Annis MG, McGuirk S, Northey JJ, Chenard V, Sriram U, Papadopoli DJ et al (2017) PGC-1\u03b1 promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell metabolism. 26(5):778\u201387","journal-title":"Cell metabolism."},{"issue":"3","key":"12615_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1152\/physrev.00030.2008","volume":"89","author":"M Liesa","year":"2009","unstructured":"Liesa M, Palacin M, Zorzano A (2009) Mitochondrial dynamics in mammalian health and disease. Physiol Rev 89(3):799\u2013845","journal-title":"Physiol Rev"},{"issue":"4","key":"12615_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cmet.2013.03.002","volume":"17","author":"M Liesa","year":"2013","unstructured":"Liesa M, Shirihai OS (2013) Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab 17(4):491\u2013506","journal-title":"Cell Metab"},{"key":"12615_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00640","volume":"9","author":"TH Patel","year":"2019","unstructured":"Patel TH, Norman L, Chang S, Abedi S, Liu C, Chwa M, Atilano SR, Thaker K, Lu S, Jazwinski SM et al (2019) European mtDNA variants are associated with differential responses to cisplatin, an anticancer drug: implications for drug resistance and side effects. Front Oncol 9:640","journal-title":"Front Oncol"},{"key":"12615_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.629614","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Li Z (2021) Potential mechanism underlying the role of mitochondria in breast cancer drug resistance and its related treatment prospects. Front Oncol 11:629614","journal-title":"Front Oncol"},{"issue":"3\u20134","key":"12615_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10911-012-9265-1","volume":"17","author":"S Wang","year":"2012","unstructured":"Wang S, Bai L, Lu J, Liu L, Yang CY, Sun H (2012) Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics. J Mammary Gland Biol Neoplasia 17(3\u20134):217\u2013228","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"10","key":"12615_CR10","doi-asserted-by":"publisher","first-page":"6456","DOI":"10.4049\/jimmunol.179.10.6456","volume":"179","author":"RD Michalek","year":"2007","unstructured":"Michalek RD, Nelson KJ, Holbrook BC, Yi JS, Stridiron D, Daniel LW, Fetrow JS, King SB, Poole LB, Grayson JM (2007) The requirement of reversible cysteine sulfenic acid formation for T cell activation and function. J Immunol 179(10):6456\u20136467","journal-title":"J Immunol"},{"issue":"8","key":"12615_CR11","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/eji.201142289","volume":"42","author":"KE Crump","year":"2012","unstructured":"Crump KE, Juneau DG, Poole LB, Haas KM, Grayson JM (2012) The reversible formation of cysteine sulfenic acid promotes B-cell activation and proliferation. Eur J Immunol 42(8):2152\u20132164","journal-title":"Eur J Immunol"},{"issue":"6","key":"12615_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1159\/000276765","volume":"77","author":"L Insabato","year":"2009","unstructured":"Insabato L, Amelio I, Quarto M, Zannetti A, Tolino F, de Mauro G, Cerchia L, Riccio P, Baumhoer D, Condorelli G et al (2009) Elevated expression of the tyrosine phosphatase SHP-1 defines a subset of high-grade breast tumors. Oncology 77(6):378\u2013384","journal-title":"Oncology"},{"key":"12615_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4","volume":"88","author":"SS Yip","year":"2000","unstructured":"Yip SS, Crew AJ, Gee JM, Blamey RW, Robertson JF, Nicholson RI, Sutherland RL, Daly RJ (2000) Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer 88:363\u2013368","journal-title":"Int J Cancer"},{"issue":"4","key":"12615_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nm.2645","volume":"18","author":"N Aceto","year":"2012","unstructured":"Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ et al (2012) Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18(4):529\u2013537","journal-title":"Nat Med"},{"issue":"17","key":"12615_CR15","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/onc.2014.170","volume":"34","author":"N Sausgruber","year":"2015","unstructured":"Sausgruber N, Coissieux MM, Britschgi A, Wyckoff J, Aceto N, Leroy C, Stadler MB, Voshol H, Bonenfant D, Bentires-Alj M (2015) Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases. Oncogene 34(17):2272\u20132278","journal-title":"Oncogene"},{"issue":"1","key":"12615_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01521-3","volume":"24","author":"G Heynen","year":"2022","unstructured":"Heynen G, Lisek K, Vogel R, Wulf-Goldenberg A, Alcaniz J, Montaudon E, Marangoni E, Birchmeier W (2022) Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. Breast Cancer Res 24(1):23","journal-title":"Breast Cancer Res"},{"issue":"49","key":"12615_CR17","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1038\/s41388-020-01488-5","volume":"39","author":"H Chen","year":"2020","unstructured":"Chen H, Libring S, Ruddraraju KV, Miao J, Solorio L, Zhang ZY, Wendt MK (2020) SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. Oncogene 39(49):7166\u20137180","journal-title":"Oncogene"},{"key":"12615_CR18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170340","author":"C Kan","year":"2024","unstructured":"Kan C, Tan Z, Liu L, Liu B, Zhan L, Zhu J, Li X, Lin K, Liu J, Liu Y et al (2024) Phase separation of SHP2E76K promotes malignant transformation of mesenchymal stem cells by activating mitochondrial complexes. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.170340","journal-title":"JCI Insight"},{"issue":"1","key":"12615_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02351-0","volume":"8","author":"W Guo","year":"2017","unstructured":"Guo W, Liu W, Chen Z, Gu Y, Peng S, Shen L, Shen Y, Wang X, Feng GS, Sun Y et al (2017) Tyrosine phosphatase SHP2 negatively regulates NLRP3 inflammasome activation via ANT1-dependent mitochondrial homeostasis. Nat Commun 8(1):2168","journal-title":"Nat Commun"},{"issue":"18","key":"12615_CR20","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00018-004-4211-z","volume":"61","author":"M Salvi","year":"2004","unstructured":"Salvi M, Stringaro A, Brunati AM, Agostinelli E, Arancia G, Clari G, Toninello A (2004) Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria. Cell Mol Life Sci 61(18):2393\u20132404","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"12615_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106788","volume":"26","author":"BA Humphries","year":"2023","unstructured":"Humphries BA, Zhang A, Buschhaus JM, Bevoor A, Farfel A, Rajendran S, Cutter AC, Luker GD (2023) Enhanced mitochondrial fission inhibits triple-negative breast cancer cell migration through an ROS-dependent mechanism. iScience 26(6):106788","journal-title":"iScience"},{"issue":"1","key":"12615_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/0008-5472.CAN-05-2853","volume":"66","author":"F Elstrodt","year":"2006","unstructured":"Elstrodt F, Hollestelle A, Nagel JHA, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP, Schutte M (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66(1):41\u201345","journal-title":"Cancer Res"},{"issue":"8","key":"12615_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.neo.2015.08.001","volume":"17","author":"SP Cavnar","year":"2015","unstructured":"Cavnar SP, Rickelmann AD, Meguiar KF, Xiao A, Dosch J, Leung BM, Cai Lesher-Perez S, Chitta S, Luker KE, Takayama S et al (2015) Modeling selective elimination of quiescent cancer cells from bone marrow. Neoplasia 17(8):625\u2013633","journal-title":"Neoplasia"},{"issue":"1","key":"12615_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13058-020-01301-x","volume":"22","author":"BA Humphries","year":"2020","unstructured":"Humphries BA, Cutter AC, Buschhaus JM, Chen YC, Qyli T, Palagama DSW, Eckley S, Robison TH, Bevoor A, Chiang B et al (2020) Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer. Breast Cancer Res 22(1):60","journal-title":"Breast Cancer Res"},{"key":"12615_CR25","doi-asserted-by":"publisher","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","volume":"64","author":"MC Smith","year":"2004","unstructured":"Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64:8604\u20138612","journal-title":"Cancer Res"},{"issue":"11","key":"12615_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nchembio.1337","volume":"9","author":"M Fallahi-Sichani","year":"2013","unstructured":"Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat Chem Biol 9(11):708\u2013714","journal-title":"Nat Chem Biol"},{"issue":"3","key":"12615_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2108","volume":"10","author":"G Honeth","year":"2008","unstructured":"Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, Grabau D, Ferno M, Borg A, Hegardt C (2008) The CD44+\/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10(3):R53","journal-title":"Breast Cancer Res"},{"issue":"4","key":"12615_CR28","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.5301\/JBM.5000048","volume":"28","author":"H Li","year":"2013","unstructured":"Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, Qian H, Xu B (2013) Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers 28(4):e357-364","journal-title":"Int J Biol Markers"},{"issue":"2","key":"12615_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.canlet.2014.06.022","volume":"353","author":"F Ma","year":"2014","unstructured":"Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, Lin C, Zhan Q, Qian H, Xu B (2014) Enriched CD44(+)\/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett 353(2):153\u2013159","journal-title":"Cancer Lett"},{"issue":"2","key":"12615_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2019.05.004","volume":"30","author":"G Civenni","year":"2019","unstructured":"Civenni G, Bosotti R, Timpanaro A, Vazquez R, Merulla J, Pandit S, Rossi S, Albino D, Allegrini S, Mitra A et al (2019) Epigenetic control of mitochondrial fission enables self-renewal of stem-like tumor cells in human prostate cancer. Cell Metab 30(2):303-318 e306","journal-title":"Cell Metab"},{"issue":"4","key":"12615_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn.3960","volume":"18","author":"Q Xie","year":"2015","unstructured":"Xie Q, Wu Q, Horbinski CM, Flavahan WA, Yang K, Zhou W, Dombrowski SM, Huang Z, Fang X, Shi Y et al (2015) Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci 18(4):501\u2013510","journal-title":"Nat Neurosci"},{"issue":"10","key":"12615_CR32","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/nchem.2778","volume":"9","author":"TT Mai","year":"2017","unstructured":"Mai TT, Hamai A, Hienzsch A, Caneque T, Muller S, Wicinski J, Cabaud O, Leroy C, David A, Acevedo V et al (2017) Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem 9(10):1025\u20131033","journal-title":"Nat Chem"},{"key":"12615_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1365-2184.36.s.1.6.x","volume":"36","author":"G Dontu","year":"2003","unstructured":"Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS (2003) Stem cells in normal breast development and breast cancer. Cell Prolif 36:59\u201372","journal-title":"Cell Prolif"},{"issue":"4","key":"12615_CR34","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-05-3153","volume":"66","author":"MS Wicha","year":"2006","unstructured":"Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea\u2014a paradigm shift. Cancer res 66(4):1883\u201390","journal-title":"Cancer res"},{"key":"12615_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","volume":"1","author":"C Ginestier","year":"2007","unstructured":"Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer C, Liu S et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555\u2013567","journal-title":"Cell Stem Cell"},{"issue":"9","key":"12615_CR36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jnci\/djn123","volume":"100","author":"X Li","year":"2008","unstructured":"Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672\u2013679","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"12615_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18610-5","volume":"8","author":"YC Chen","year":"2018","unstructured":"Chen YC, Humphries B, Brien R, Gibbons AE, Chen YT, Qyli T, Haley HR, Pirone ME, Chiang B, Xiao A et al (2018) Functional isolation of tumor-initiating cells using microfluidic-based migration identifies phosphatidylserine decarboxylase as a key regulator. Sci Rep 8(1):244","journal-title":"Sci Rep"},{"issue":"2","key":"12615_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1982","volume":"10","author":"CM Fillmore","year":"2008","unstructured":"Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10(2):R25","journal-title":"Breast Cancer Res"},{"issue":"12","key":"12615_CR39","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1158\/1078-0432.CCR-08-1479","volume":"15","author":"T Tanei","year":"2009","unstructured":"Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15(12):4234\u20134241","journal-title":"Clin Cancer Res"},{"issue":"7239","key":"12615_CR40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nature07733","volume":"458","author":"M Diehn","year":"2009","unstructured":"Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780\u2013783","journal-title":"Nature"},{"key":"12615_CR41","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.230755","author":"B Spurlock","year":"2019","unstructured":"Spurlock B, Gupta P, Basu MK, Mukherjee A, Hjelmeland AB, Darley-Usmar V, Parker D, Foxall ME, Mitra K (2019) New quantitative approach reveals heterogeneity in mitochondrial structure-function relations in tumor-initiating cells. J Cell Sci. https:\/\/doi.org\/10.1242\/jcs.230755","journal-title":"J Cell Sci"},{"issue":"5","key":"12615_CR42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","volume":"26","author":"SC Bresler","year":"2014","unstructured":"Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW et al (2014) ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 26(5):682\u2013694","journal-title":"Cancer Cell"},{"issue":"7","key":"12615_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21(7):440\u2013446","journal-title":"Pharmacogenet Genomics"},{"key":"12615_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1128\/AAC.9.4.655","volume":"9","author":"M Mitani","year":"1976","unstructured":"Mitani M, Yamanishi T, Miyazaki Y, Otake N (1976) Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother 9:655\u2013660","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"12615_CR45","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.bbamcr.2013.04.011","volume":"1833","author":"JR Jangamreddy","year":"2013","unstructured":"Jangamreddy JR, Ghavami S, Grabarek J, Kratz G, Wiechec E, Fredriksson BA, Rao Pariti RK, Cieslar-Pobuda A, Panigrahi S, Los MJ (2013) Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between primary and cancer cells. Biochim Biophys Acta 1833(9):2057\u20132069","journal-title":"Biochim Biophys Acta"},{"issue":"29","key":"12615_CR46","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/s41388-022-02385-9","volume":"41","author":"JM Buschhaus","year":"2022","unstructured":"Buschhaus JM, Rajendran S, Humphries BA, Cutter AC, Muniz AJ, Ciavattone NG, Buschhaus AM, Caneque T, Nwosu ZC, Sahoo D et al (2022) Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer. Oncogene 41(29):3705\u20133718","journal-title":"Oncogene"},{"issue":"1","key":"12615_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41420-025-02653-z","volume":"11","author":"YY Jeong","year":"2025","unstructured":"Jeong YY, Hwang J, Park A, Cho S, Cho I, Won S, Shin YM, Kim SE, Maeng CH, Yang J et al (2025) Targeting iron regulatory protein 2 (IRP2) to disrupt iron metabolism enhances radiosensitivity through mitochondrial dysfunction in breast cancer cells. Cell Death Discov 11(1):357","journal-title":"Cell Death Discov"},{"issue":"5","key":"12615_CR48","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3892\/ijo.2013.2063","volume":"43","author":"VF Chekhun","year":"2013","unstructured":"Chekhun VF, Lukyanova NY, Burlaka CA, Bezdenezhnykh NA, Shpyleva SI, Tryndyak VP, Beland FA, Pogribny IP (2013) Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol 43(5):1481\u20131486","journal-title":"Int J Oncol"},{"issue":"11","key":"12615_CR49","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1016\/j.celrep.2019.05.041","volume":"27","author":"J Celis-Gutierrez","year":"2019","unstructured":"Celis-Gutierrez J, Blattmann P, Zhai Y, Jarmuzynski N, Ruminski K, Gregoire C, Ounoughene Y, Fiore F, Aebersold R, Roncagalli R et al (2019) Quantitative interactomics in primary T cells provides a rationale for concomitant PD-1 and BTLA coinhibitor blockade in cancer immunotherapy. Cell rep 27(11):3315\u201330","journal-title":"Cell rep"},{"issue":"1","key":"12615_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/hep.26640","volume":"59","author":"WT Tai","year":"2014","unstructured":"Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF (2014) Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology 59(1):190\u2013201","journal-title":"Hepatology"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12615-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12615-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12615-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:08:10Z","timestamp":1787656090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12615-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12615"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12615-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1459"}}